U.S. markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4500+0.0500 (+1.14%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.4000
Open4.4700
Bid4.4000 x 1000
Ask4.4500 x 1000
Day's Range4.2500 - 4.4744
52 Week Range2.8100 - 9.0000
Volume530,606
Avg. Volume4,228,466
Market Cap67.684M
Beta (5Y Monthly)1.69
PE Ratio (TTM)4.60
EPS (TTM)0.9670
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment
    GlobeNewswire

    BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

    NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT™, with I

  • BriaCell to Present at Three Upcoming Investor Conferences
    GlobeNewswire

    BriaCell to Present at Three Upcoming Investor Conferences

    BERKELEY, Calif. and VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in the following virtual conferences: Access to Giving Virtual Investor conference: July 13 – 15,

  • ACCESSWIRE

    50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

    RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th \- 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.